Keppra - Revision history

Lazy at 08:16, 18 January 2025

2025-01-18T08:16:15Z

← Older revision		Revision as of 01:16, 18 January 2025
Line 15:		Line 15:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		\|overview=Keppra (Levetiracetam) is an FDA-approved anti-seizure medication used for seizure prevention in brain tumor patients, with emerging evidence suggesting it may enhance the efficacy of temozolomide chemotherapy. Clinical studies have indicated improved overall and progression-free survival rates for glioblastoma patients taking Keppra, making it a promising option in this context, although further research is needed to fully understand its benefits.}}

69.163.248.232 at 18:58, 12 November 2024

2024-11-12T18:58:11Z

← Older revision		Revision as of 11:58, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.		\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
	\|~~treatment_treatment_treatment_treatment_category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:22:41Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:22, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.		\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
	\|~~treatment_treatment_treatment_category~~=Repurposed Drugs		\|treatment_treatment_treatment_treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:16:10Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:16, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.		\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
	\|~~treatment_treatment_category~~=Repurposed Drugs		\|treatment_treatment_treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:15:08Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:15, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.		\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
	\|~~treatment_category~~=Repurposed Drugs		\|treatment_treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:13:30Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:13, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.		\|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.		\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

Lazy at 16:51, 27 March 2024

2024-03-27T16:51:23Z

← Older revision		Revision as of 09:51, 27 March 2024
Line 13:		Line 13:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=Keppra (Levetiracetam) is generally well-tolerated when used in the treatment of glioblastoma. Its side effects including fatigue, dizziness, and mood changes are fairly mild. However, like all medication, it does come with some level of toxicity which is why it's ranked at a 2 on a scale of 1 to 5. It's important to always discuss potential side effects with your healthcare provider to ensure this treatment is a good fit for you.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Keppra (Levetiracetam) |FDA_approval=Yes (as an anti-seizure medication, 1999) |used_for=Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy |clinical_trial_phase=Retrospective studies and laboratory research |common_side_effects=Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor..."

2024-03-19T16:35:53Z

Created page with "{{TreatmentInfo |drug_name=Keppra (Levetiracetam) |FDA_approval=Yes (as an anti-seizure medication, 1999) |used_for=Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy |clinical_trial_phase=Retrospective studies and laboratory research |common_side_effects=Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor..."

New page

{{TreatmentInfo
|drug_name=Keppra (Levetiracetam)
|FDA_approval=Yes (as an anti-seizure medication, 1999)
|used_for=Seizure prevention in brain tumor patients, potential sensitizer for glioblastoma cells to temozolomide chemotherapy
|clinical_trial_phase=Retrospective studies and laboratory research
|common_side_effects=Common side effects associated with Keppra include fatigue, dizziness, and mood changes, but it is generally well-tolerated in the context of brain tumor treatment.
|OS_without=Median OS for glioblastoma patients not taking Keppra: 16.7 months
|OS_with=Median OS for glioblastoma patients taking Keppra during chemotherapy: 25.7 months
|PFS_without=Median PFS for patients not taking Keppra: 6.7 months
|PFS_with=Median PFS for patients taking Keppra: 9.4 months
|usefulness_rating=4
|notes=Keppra has become a prevalent choice for seizure prevention in brain tumor patients, with emerging evidence suggesting it can also enhance the efficacy of temozolomide chemotherapy by inhibiting MGMT enzyme activity. Significant increases in progression-free and overall survival were observed in patients receiving Keppra alongside chemotherapy in a retrospective study. Further research is needed to understand the full scope of benefits and whether they extend to patients with unmethylated MGMT status.
|category=Repurposed Drugs
|links=
}}